Table 2:
Summary of studies evaluating syphilis POCTs in countries with a low prevalence of syphilis
| Assay and country | Study | Sens | Spec | Lab | Field | Serum | Whole blood |
|---|---|---|---|---|---|---|---|
| Determine™ Syphilis TP | |||||||
| United Kingdom | Perry et al (21) | 91.3 | 100 | X | X | ||
| Australia | Causer et al (22) | 97.3 | 96.4 | X | X | ||
| SD Bioline | |||||||
| Italy | Zorzi et al (23) | 51.0–80.0 | 100 | X | X | X | |
| Australia | Causer et al (22) | 87.8 | 98.5 | X | X | X | |
| Canada | Morshed (unpublished personal communication) | Sens 85.0 Spec 100 |
Sens 95.0 Spec 100 |
Sens 85.0 Spec 100 |
Sens 95.0 Spec 100 |
||
| DPP® Syphilis Screen and Confirm | |||||||
| Italy | Zorzi et al (23) | 57.7–65.4 | 99.5 | X | X | X | |
| France | Guinard et al (24) | >90% | >90% | X | X | ||
| Australia | Causer et al (22) | 89.8 | 98.3 | X | X | ||
| Australia | Skinner et al (25) | 95.6 | 66.2 | X | X | ||
| Canada | Caya et al (26) | 91.0 | 100 | X | X | ||
| Portugal | Castro et al (27) | 98.8 | 94.7 | X | X | ||
| Syphilis Health Check™ | |||||||
| United States | Obafemi et al (28) | 90.0 | 98.5 | X | X | ||
| United States | Matthias et al (29) | 71.4 | 91.5 | X | X | ||
| Onsite™ Syphilis Ab Rapid Test | |||||||
| Australia | Causer et al (22) | 92.5 | 97.0 | X | X |
POCTs = Point-of-care tests; Sens = Sensitivity; Spec = Specificity; Lab = Laboratory